Document is current

Any future updates will be listed below

A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin

Crossref DOI link: https://doi.org/10.1186/s12902-017-0219-x

Published Online: 2017-11-06

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark